Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma
Conditions
- Glioma
- Diffuse Glioma
- Recurrent Gliomas
Interventions
- DRUG: Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma.
Sponsor
Huashan Hospital
Collaborators